{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T14:33:58Z","timestamp":1780929238027,"version":"3.54.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,12]],"date-time":"2026-12-12T00:00:00Z","timestamp":1797033600000},"content-version":"am","delay-in-days":376,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R35GM143044"],"award-info":[{"award-number":["R35GM143044"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011082","name":"University of North Carolina at Chapel Hill School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011082","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["S10OD032350 (2023"],"award-info":[{"award-number":["S10OD032350 (2023"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["S10RR024595"],"award-info":[{"award-number":["S10RR024595"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006808","name":"University of North Carolina","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006808","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.dmd.2025.100196","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T16:01:11Z","timestamp":1762185671000},"page":"100196","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Interindividual variability in imatinib metabolism in human liver microsomes and primary human hepatocytes: Impact of CYP2C8 and CYP3A phenotypes"],"prefix":"10.1016","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9770-5159","authenticated-orcid":false,"given":"Bethany D.","family":"Latham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pegah","family":"Montazeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6212-8291","authenticated-orcid":false,"given":"Raeanne M.","family":"Lanphier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4643-8622","authenticated-orcid":false,"given":"Amanda J.","family":"Gerringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8532-2733","authenticated-orcid":false,"given":"Tyler","family":"Interrante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corbin D.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"De Busysscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1848-0121","authenticated-orcid":false,"given":"John K.","family":"Fallon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9388-9800","authenticated-orcid":false,"given":"Klarissa D.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.dmd.2025.100196_bib2","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.dmd.2025.100196_bib3","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1200\/JCO.2004.03.050","article-title":"Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients","volume":"22","author":"Peng","year":"2004","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.dmd.2025.100196_bib4","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/j.1476-5381.2010.00946.x","article-title":"Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes","volume":"161","author":"Nebot","year":"2010","journal-title":"Br J Pharmacol"},{"issue":"3","key":"10.1016\/j.dmd.2025.100196_bib5","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3109\/00498254.2015.1060649","article-title":"Impact of CYP2C8\u22173 polymorphism on in vitro metabolism of imatinib to N-desmethyl imatinib","volume":"46","author":"Khan","year":"2016","journal-title":"Xenobiotica"},{"issue":"1","key":"10.1016\/j.dmd.2025.100196_bib6","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1124\/dmd.112.048017","article-title":"Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response","volume":"41","author":"Filppula","year":"2013","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"10.1016\/j.dmd.2025.100196_bib7","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1111\/j.1476-5381.2011.01732.x","article-title":"Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates","volume":"165","author":"Filppula","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.dmd.2025.100196_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112090","article-title":"Influence of genetic polymorphisms on imatinib concentration and therapeutic response in patients with chronic-phase chronic myeloid leukemia","volume":"133","author":"Cheng","year":"2024","journal-title":"Int Immunopharmacol"},{"issue":"8","key":"10.1016\/j.dmd.2025.100196_bib9","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s40262-016-0494-0","article-title":"CYP2C8 genotype significantly alters imatinib metabolism in chronic myeloid leukaemia patients","volume":"56","author":"Barratt","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.dmd.2025.100196_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117511","article-title":"Effect of recombinant CYP3A4 variants and interaction on imatinib metabolism in vitro","volume":"180","author":"Chen","year":"2024","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"10.1016\/j.dmd.2025.100196_bib11","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3390\/ijms18030603","article-title":"Genetic polymorphisms contribute to the individual variations of imatinib mesylate plasma levels and adverse reactions in Chinese GIST patients","volume":"18","author":"Liu","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.dmd.2025.100196_bib12","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.5114\/aoms.2018.73538","article-title":"The significance of enzyme and transporter polymorphisms for imatinib plasma levels and achieving an optimal response in chronic myeloid leukemia patients","volume":"14","author":"Belohlavkova","year":"2018","journal-title":"Arch Med Sci"},{"issue":"3","key":"10.1016\/j.dmd.2025.100196_bib13","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1093\/annonc\/mds532","article-title":"Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients","volume":"24","author":"Seong","year":"2013","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.dmd.2025.100196_bib14","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/leu.2015.36","article-title":"Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV","volume":"29","author":"Kalmanti","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.dmd.2025.100196_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2024.102016","article-title":"Imatinib therapy of chronic myeloid leukemia significantly reduces carnitine cell intake, resulting in adverse events","volume":"88","author":"Burda","year":"2024","journal-title":"Mol Metab"},{"issue":"1","key":"10.1016\/j.dmd.2025.100196_bib16","doi-asserted-by":"crossref","first-page":"181","DOI":"10.4143\/crt.2019.131","article-title":"Factors influencing imatinib-induced hepatotoxicity","volume":"52","author":"Han","year":"2020","journal-title":"Cancer Res Treat"},{"issue":"5","key":"10.1016\/j.dmd.2025.100196_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100061","article-title":"Impact of variation in CYP3A and CYP2C8 on tucatinib metabolic clearance in human liver microsomes","volume":"53","author":"Latham","year":"2025","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2025.100196_bib18","year":"2023"},{"issue":"9","key":"10.1016\/j.dmd.2025.100196_bib19","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1021\/acs.chemrestox.2c00057","article-title":"Cytochromes P450 2C8 and 3A catalyze the metabolic activation of the tyrosine kinase inhibitor masitinib","volume":"35","author":"Latham","year":"2022","journal-title":"Chem Res Toxicol"},{"issue":"10","key":"10.1016\/j.dmd.2025.100196_bib20","doi-asserted-by":"crossref","first-page":"4402","DOI":"10.1021\/pr4004213","article-title":"Targeted quantitative proteomics for the analysis of 14 UGT1As and -2Bs in human liver using NanoUPLC-MS\/MS with selected reaction monitoring","volume":"12","author":"Fallon","year":"2013","journal-title":"J Proteome Res"},{"key":"10.1016\/j.dmd.2025.100196_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2019.106590","article-title":"Targeted quantitative proteomic analysis of drug metabolizing enzymes and transporters by nano LC-MS\/MS in the sandwich cultured human hepatocyte model","volume":"98","author":"Khatri","year":"2019","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1016\/j.dmd.2025.100196_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1218703","article-title":"Pregnancy related hormones increase CYP3A mediated buprenorphine metabolism in human hepatocytes: a comparison to CYP3A substrates nifedipine and midazolam","volume":"14","author":"Fashe","year":"2023","journal-title":"Front Pharmacol"},{"issue":"D1","key":"10.1016\/j.dmd.2025.100196_bib45","doi-asserted-by":"crossref","first-page":"D543","DOI":"10.1093\/nar\/gkab1038","article-title":"The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences","volume":"50","author":"Perez-Riverol","year":"2022","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"10.1016\/j.dmd.2025.100196_bib23","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1124\/dmd.32.6.647","article-title":"Validated assays for human cytochrome P450 activities","volume":"32","author":"Walsky","year":"2004","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmd.2025.100196_bib24","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/gim.2016.87","article-title":"Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC)","volume":"19","author":"Caudle","year":"2017","journal-title":"Genet Med"},{"issue":"4","key":"10.1016\/j.dmd.2025.100196_bib25","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00228-009-0772-y","article-title":"CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity","volume":"66","author":"Gr\u00e9en","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.dmd.2025.100196_bib26","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.1082","article-title":"Application of physiologically based pharmacokinetic modeling to understand real-world outcomes in patients receiving imatinib for chronic myeloid leukemia","volume":"11","author":"Adattini","year":"2023","journal-title":"Pharmacol Res Perspect"},{"issue":"6","key":"10.1016\/j.dmd.2025.100196_bib27","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/bjh.13649","article-title":"Sex correlates with differences in long-term outcome in chronic myeloid leukaemia patients treated with imatinib","volume":"173","author":"Breccia","year":"2016","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.dmd.2025.100196_bib28","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.clpt.2006.08.014","article-title":"Sex differences in CYP3A activity using intravenous and oral midazolam","volume":"80","author":"Chen","year":"2006","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.dmd.2025.100196_bib29","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/FPC.0000000000000278","article-title":"Influence of CYP2C8 polymorphisms on imatinib steady-state trough level in chronic myeloid leukemia and gastrointestinal stromal tumor patients","volume":"27","author":"Verboom","year":"2017","journal-title":"Pharmacogenet Genomics"},{"issue":"3","key":"10.1016\/j.dmd.2025.100196_bib30","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/bcp.15551","article-title":"CYP2D6 and CYP2C8 pharmacogenetics and pharmacological interactions to predict imatinib plasmatic exposure in GIST patients","volume":"89","author":"Dalle Fratte","year":"2023","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.dmd.2025.100196_bib31","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1124\/pr.115.011411","article-title":"Role of cytochrome P450 2C8 in drug metabolism and interactions","volume":"68","author":"Backman","year":"2016","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.dmd.2025.100196_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2021.109700","article-title":"Functional evaluation of vandetanib metabolism by CYP3A4 variants and potential drug interactions in vitro","volume":"350","author":"Han","year":"2021","journal-title":"Chem Biol Interact"},{"issue":"4","key":"10.1016\/j.dmd.2025.100196_bib33","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/bcpt.12934","article-title":"Functional characterization of 22 CYP3A4 protein variants to metabolize ibrutinib in vitro","volume":"122","author":"Xu","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"9","key":"10.1016\/j.dmd.2025.100196_bib34","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jmoldx.2023.06.008","volume":"25","author":"Pratt","year":"2023","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.dmd.2025.100196_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2024.101029","article-title":"Genetic variation present in the CYP3A4 gene in Ni-Vanuatu and Kenyan populations in malaria endemicity","volume":"57","author":"Musyoka","year":"2024","journal-title":"Drug Metab Pharmacokinet"},{"issue":"4","key":"10.1016\/j.dmd.2025.100196_bib36","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1179\/1607845412Y.0000000067","article-title":"Do SLCO1B3 (T334G) and CYP3A5\u22173 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving imatinib therapy?","volume":"18","author":"Bedewy","year":"2013","journal-title":"Hematology"},{"key":"10.1016\/j.dmd.2025.100196_bib37","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.phrs.2018.02.005","article-title":"Impact of SLC22A1 and CYP3A5 genotypes on imatinib response in chronic myeloid leukemia: a systematic review and meta-analysis","volume":"131","author":"Cargnin","year":"2018","journal-title":"Pharmacol Res"},{"issue":"11","key":"10.1016\/j.dmd.2025.100196_bib38","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/jhg.2010.98","article-title":"Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia","volume":"55","author":"Takahashi","year":"2010","journal-title":"J Hum Genet"},{"issue":"5","key":"10.1016\/j.dmd.2025.100196_bib39","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/jcpt.12424","article-title":"Influence of CYP3A5\u22173 and ABCB1 C3435T on clinical outcomes and trough plasma concentrations of imatinib in Nigerians with chronic myeloid leukaemia","volume":"41","author":"Adeagbo","year":"2016","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"10.1016\/j.dmd.2025.100196_bib40","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s00280-024-04723-y","article-title":"Influence of CYP2C8\u22173 and ABCG2 C421A genetic polymorphisms on trough concentration and molecular response of imatinib in Egyptian patients with chronic myeloid leukemia","volume":"95","author":"Mangoura","year":"2024","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"10.1016\/j.dmd.2025.100196_bib41","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1038\/sj.bjc.6601152","article-title":"Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia","volume":"89","author":"O'Brien","year":"2003","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.dmd.2025.100196_bib42","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/bcp.12723","article-title":"Human hepatocyte assessment of imatinib drug-drug interactions\u2014complexities in clinical translation","volume":"80","author":"Beumer","year":"2015","journal-title":"Br J Clin Pharmacol"},{"issue":"24","key":"10.1016\/j.dmd.2025.100196_bib43","doi-asserted-by":"crossref","first-page":"7394","DOI":"10.1158\/1078-0432.CCR-07-0346","article-title":"Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib","volume":"13","author":"van Erp","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.dmd.2025.100196_bib44","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/cpt.690","article-title":"Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects","volume":"102","author":"Zhou","year":"2017","journal-title":"Clin Pharmacol Ther"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625095054?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625095054?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T14:59:01Z","timestamp":1777474741000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955625095054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":44,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0090955625095054"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100196","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interindividual variability in imatinib metabolism in human liver microsomes and primary human hepatocytes: Impact of CYP2C8 and CYP3A phenotypes","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100196","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100196"}}